Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial

Reema Thottol; Ancy George; Laxmi G

doi:10.5455/njppp.2022.12.04159202221042022

2024, Vol: 14, Issue: 12

14 / 12Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form

« Previous Article

Original Research
Online Published: 29 Apr 2022

Natl J Physiol Pharm Pharmacol. 2022; 12(6): 823-827

doi: 10.5455/njppp.2022.12.04159202221042022

Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial

Reema Thottol, Ancy George, Laxmi G.

Abstract
Background: The ever-increasing prevalence of diabetes has led to a higher incidence of progression into complications including nephropathy. Diabetic kidney disease (DKD) is a chronic condition that is managed with renin-angiotensin-aldosterone system blockers which retard its progression. Pentoxifylline as an add-on therapy has been tried for reducing
DKD.

Aims and Objectives: The aims of this study were to study the safety and efficacy of pentoxifylline added on to an angiotensin II receptor blocker (ARB) to reduce the progression of the disease condition in diabetic nephropathy (DN) patients over 1 year.

Materials and Methods: It is a randomized open-label study conducted in the Department of Nephrology, of a tertiary care center for 1 year. Type 2 diabetes patients with DN who satisfied the eligibility criteria were randomized into pentoxifylline added on to ARB or ARB alone and followed up for urine albumin-creatinine ratio (ACR) and serum tumor necrosis factor (TNF)-alpha.

Results: Twenty-six patients were recruited and completed the study. Urine ACR was significantly low in the pentoxifylline group compared to the ARB alone group (P = 0.021). Serum TNF-α was decreased in the pentoxifylline group in comparison to the ARB alone group (P = 0.06).

Conclusion: Pentoxifylline caused significant lowering of urinary ACR and urine TNF-α for 4 months.

Key words: Diabetic Nephropathy; Pentoxifylline; Urine Albumin/Creatinine Ratio; Urine Tumor Necrosis Factor-α

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Reema Thottol Articles by Ancy George Articles by Laxmi G
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Thottol R, George A, G L. Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. Natl J Physiol Pharm Pharmacol. 2022; 12(6): 823-827. doi:10.5455/njppp.2022.12.04159202221042022

Web Style

Thottol R, George A, G L. Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. https://www.njppp.com/?mno=8105 [Access: January 18, 2025]. doi:10.5455/njppp.2022.12.04159202221042022

AMA (American Medical Association) Style

Thottol R, George A, G L. Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. Natl J Physiol Pharm Pharmacol. 2022; 12(6): 823-827. doi:10.5455/njppp.2022.12.04159202221042022

Vancouver/ICMJE Style

Thottol R, George A, G L. Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. Natl J Physiol Pharm Pharmacol. (2022), [cited January 18, 2025]; 12(6): 823-827. doi:10.5455/njppp.2022.12.04159202221042022

Harvard Style

Thottol, R., George, . A. & G, . L. (2022) Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. Natl J Physiol Pharm Pharmacol, 12 (6), 823-827. doi:10.5455/njppp.2022.12.04159202221042022

Turabian Style

Thottol, Reema, Ancy George, and Laxmi G. 2022. Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. National Journal of Physiology, Pharmacy and Pharmacology, 12 (6), 823-827. doi:10.5455/njppp.2022.12.04159202221042022

Chicago Style

Thottol, Reema, Ancy George, and Laxmi G. "Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 823-827. doi:10.5455/njppp.2022.12.04159202221042022

MLA (The Modern Language Association) Style

Thottol, Reema, Ancy George, and Laxmi G. "Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial." National Journal of Physiology, Pharmacy and Pharmacology 12.6 (2022), 823-827. Print. doi:10.5455/njppp.2022.12.04159202221042022

APA (American Psychological Association) Style

Thottol, R., George, . A. & G, . L. (2022) Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial. National Journal of Physiology, Pharmacy and Pharmacology, 12 (6), 823-827. doi:10.5455/njppp.2022.12.04159202221042022

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Digital Archiving & Preservation Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article